|
Volume
15 Number 9
30 September 2015
|
|
Home
>
Publications
>
Current
Neuro-Oncology >
Volume
17, Year 2015 >
Number 9, 30 September
|
|
|
|
|
|
Chang
W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai
A, Cloughesy TF, Ellingson BM.
Diffusion
MR Characteristics Following Concurrent Radiochemotherapy Predicts
Progression-Free and Overall Survival in Newly Diagnosed
Glioblastoma.
Tomography.
2015 Sep 1;1(1):37-43🡥.
doi:
10.18383/j.tom.2015.00115🡥.
PMID:
26740971🡥
Observational study. _
|
|
|
|
Itakura
H, Achrol AS, Mitchell LA, Loya JJ, Liu T, Westbroek EM, Feroze
AH, Rodriguez S, Echegaray S, Azad TD, Yeom KW, Napel S, Rubin DL,
Chang SD, Harsh GR 4th, Gevaert O.
Magnetic
resonance image features identify glioblastoma phenotypic subtypes
with distinct molecular pathway activities.
Sci
Transl Med.
2015 Sep 2;7(303):303ra138. doi: 10.1126/scitranslmed.aaa7582.
Clinical tool development. _
|
|
|
|
Eaton
BR, Esiashvili N, Kim S, Weyman EA, Thornton LT, Mazewski C,
MacDonald T, Ebb D, MacDonald SM, Tarbell NJ, Yock TI.
Clinical
Outcomes Among Children With Standard-Risk Medulloblastoma Treated
With Proton and Photon Radiation Therapy: A Comparison of Disease
Control and Overall Survival.
Int
J Radiat Oncol Biol Phys. 2015 Sep 17, 2016;94(1):133-8🡥.
doi: 10.1016/j.ijrobp.2015.09.014🡥.
PMID: 26700707🡥.
Observational study. 🡥
|
|
|
|
Rutledge
MR, Waddell JA, Solimando DA Jr.
Bevacizumab
and Temozolomide Plus Radiation Regimen for Glioblastoma
Multiforme.
Hosp
Pharm. 2015 Sep 16, 2015;50(8):672-7. doi: 10.1310/hpj5008-672.
Source
Similar
articles
|
|
|
|
Chamberlain
MC.
Phase
II study of monthly pasireotide LAR (SOM230C) for recurrent or
progressive meningioma.
Neurology.
2015 Sep 21;85(12):1090🡥.
doi: 10.1212/WNL.0000000000001988🡥.
PMID: 26391415🡥.
Comment. 🡥
Refers
to:
Norden AD, et al., Phase
II study of monthly pasireotide LAR (SOM230C) for recurrent or
progressive meningioma.
Neurology.
2014 Dec 19, 2015;84(3):280-6. doi:
10.1212/WNL.0000000000001153🡥.
PMID: 25527270🡥.
Interventional study. 🡥
|
|
|
|
Wen
PY, Norden AD.
Author
response.
Neurology.
2015 Sep 22;85(12):1090. PMID: 26645061.🡥
Comment.
🡥
Refers
to:
Chamberlain MC., Phase
II study of monthly pasireotide LAR (SOM230C) for recurrent or
progressive meningioma.
Neurology.
2015 Sep 21;85(12):1090🡥.
doi: 10.1212/WNL.0000000000001988🡥.
PMID: 26391415🡥.
Comment. 🡥
In
turn referring to:
Norden AD, et al., Phase
II study of monthly pasireotide LAR (SOM230C) for recurrent or
progressive meningioma.
Neurology.
2014 Dec 19, 2015;84(3):280-6. doi:
10.1212/WNL.0000000000001153🡥.
PMID: 25527270🡥.
Interventional study. 🡥
|
|
|
|
Lombardi
G, Pace A, Pasqualetti F, Rizzato S, Faedi M, Anghileri E,
Nicolotto E, Bazzoli E, Bellu L, Villani V, Fabi A, Ferrazza P,
Gurrieri L, Dall'Agata M, Eoli M, Della Puppa A, Pambuku A,
D'Avella D, Berti F, Rudà R, Zagonel V.
Predictors
of survival and effect of short (40 Gy) or standard-course (60 Gy)
irradiation plus concomitant temozolomide in elderly patients with
glioblastoma: a multicenter retrospective study of AINO (Italian
Association of Neuro-Oncology).
J
Neurooncol. 2015 Sep 30; 2015;125(2):359-67. doi:
10.1007/s11060-015-1923-x. Source
|
Abstract
|
Full
text |
Similar
articles
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
